ArticleAnnals of hematology2026
Cooling immunochemotherapy and hematopoietic stem cell transplantation for refractory systemic epstein-barr virus-positive T-cell lymphoma in children: a single institution experience.
Article in Annals of hematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic Epstein-Barr virus-positive T-cell lymphoma (SEBVTL) of childhood is a rare and aggressive disorder often associated with hemophagocytic lymphohistiocytosis (HLH) and multiorgan failure. We reviewed six pediatric SEBVTL cases treated at Seoul National University Children’s Hospital between 2017 and 2024. All patients presented with HLH and bone marrow involvement. Initial management included the HLH-2004 protocol and chemotherapy. Since December 2022, cooling immunochemotherapy (etoposide and cytarabine) was introduced as a bridge to hematopoietic stem cell transplantation (HSCT). Median age at diagnosis was 8.2 years, and median follow-up was 8.5 months. Three patients treated before 2022 died of progressive disease. Among three patients managed with cooling immunochemotherapy and HSCT, two survived and one died of engraftment failure. The 1-year overall and event-free survival rates were both 33.3%. These findings suggest cooling immunochemotherapy followed by HSCT may improve outcomes in refractory pediatric SEBVTL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.